title: [Management of anaemia in patient with cancer: results of the F-ACT study (French Anaemia Cancer Treatment)].
abstract: Anaemia is one of the most dreaded complications among patients with malignant pathologies. Its causes can be varied and whatever its severity, the impact on the quality of life of the patient remains essential. However, the epidemiologic data concerning anaemia are very few in the literature. This is why we carried out a large national survey about the prevalence and the management of anaemia among patients with malignant diseases. The F-ACT (French Anaemia Cancer Treatment) study is a retrospective observational multicentric study conducted with 178 experts practicing in 112 centers or units treating patients with solid tumours and/or malignant haematological diseases. Control over one day standard of consultation for each questioned expert, 2 782 patients were enrolled, including 1 892 (68%) patient with solid tumour and 890 (27%) patient with malignant haematological disease. The median age was 61 years (range : 18-93 years) including 1 335 women (48%) and 1 447 men (52%). A the date of enrollment, the median level of haemoglobin (Hb) was 11,6 g/dl (range: 5,2-18,5 g/dl) and 44% of patient had a level of Hb < 11 g/dl. An anaemia was found in all the cancer localizations and whatever the stage or the therapeutic status of the disease. Approximately 2/3 of the anaemic patients received treatment by erythropoiesis stimulating agent (ESA) and approximately 17% of them did not receive any specific treatment for this anaemia. The median level of Hb at the introduction of the ESA was 10 g/dl. These results, compared with those reported in study ECAS (European Cancer Anaemia Survey) in 2001, seem to show an improvement in the management of anaemia and the use of the ESA, in particular an earlier introduction of this type of treatment since the appearance of anaemia.
authors.affiliation: CHU Jean Minjoz, Service oncologie médicale, 3, bd Fleming, 25030 Besançon Cedex. eguardiola@chu-besancon.fr
authors.forename: Emmanuel
authors.initials: E
authors.lastname: Guardiola
authors.forename: Franck
authors.initials: F
authors.lastname: Morschhauser
authors.forename: Jean-Jacques
authors.initials: JJ
authors.lastname: Zambrowski
authors.forename: Eric-Charles
authors.initials: EC
authors.lastname: Antoine
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000740:Anemia / Q000453:epidemiology / Q000209:etiology / Q000628:therapy*; D001803:Blood Transfusion / Q000706:statistics & numerical data; D004920:Erythropoiesis; D005260:Female; D005602:France / Q000453:epidemiology; D019538:Health Care Surveys; D006397:Hematinics / Q000627:therapeutic use; D019337:Hematologic Neoplasms / Q000150:complications; D006441:Hemoglobin A / Q000032:analysis; D006801:Humans; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000150:complications* / Q000473:pathology; D015995:Prevalence; D012189:Retrospective Studies
chemical_list: D006397:Hematinics; D006441:Hemoglobin A